Loading viewer...
investor_presentation
Format: PDF investor_presentation
Swiss biotech company based at EPFL Innovation Park developing breakthrough immuno-oncology therapies. ACB1801, a tumor reversion agent, demonstrates 65% survival improvement when combined with anti-PD-1 drugs in melanoma models. Pipeline targets multi-billion dollar market with estimated peak sales of $2.2 billion and proof-of-concept expected in 2024.
investor_presentation
55 Pages
Power Integrations, Inc.
Mitsubishi Chemical Group 2022 IR Day Performance Products
investor_presentationinvestor_presentation
61 Pages
Mitsubishi Chemical Group Corporation
Aptus Value Housing Finance Q3 FY23 Investor Presentation
investor_presentationinvestor_presentation
34 Pages
Aptus Value Housing Finance India Limited